Else Nutrition Holdings Inc (BABYF) Q2 2024 Earnings Call Highlights: Strong Retail Growth and ...

In This Article:

  • Revenue: $2.6 million for Q2 2024, a 23% increase from Q1 2024.

  • Retail Sales Growth: Increased 88% in the US and 111% in Canada sequentially.

  • Gross Profit: Improved to 10% in Q2 2024 from a gross loss of 2% in Q2 2023.

  • Operating Expenses: Decreased to $3.4 million in Q2 2024 from $4.2 million in Q2 2023.

  • Walmart Store Expansion: Products added to an additional 600 Walmart stores, totaling 1,400 stores in the US.

  • New Retail Partnerships: Onboarded retailers include Wegmans, HEB, Meijer, and others.

  • Ready-to-Drink (RTD) Products: Entered six US retailers and four Canadian retailers.

  • Customer Acquisition Cost: Achieved as low as $7 for new customers.

Release Date: August 14, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Else Nutrition Holdings Inc (BABYF) reported a significant sequential revenue increase of 23% for the second quarter of 2024, driven by strong growth in US and Canadian retailers.

  • The company successfully expanded its retail presence, adding products to 600 additional Walmart stores in the US, and entering walmart.ca in Canada.

  • Else Nutrition's ready-to-drink (RTD) products have gained significant traction, earning the prestigious Mom's Choice Award and entering multiple US and Canadian retailers.

  • The company has improved its gross profit margin, achieving a 10% gross profit in Q2 2024 compared to a gross loss in the same quarter of the previous year.

  • Else Nutrition is making progress in reducing production costs and improving product quality through new partnerships, including a new US powder plant and plans for a European facility.

Negative Points

  • The company's stock price remains a concern for shareholders, with management acknowledging frustration over its current valuation.

  • Else Nutrition has not yet received FDA confirmation for its plant-based infant formula, limiting its ability to move forward with clinical trials in the US.

  • The letter of intent with a large organization, Xenon, has expired, and macro political events may be delaying further discussions.

  • Despite progress, the company is not yet cash flow positive and estimates it will take 18 to 24 months to achieve this goal.

  • The launch of the adult RTD product line is still in the planning stages, with commercial production expected in Q3 2024 and a full launch in early 2025.

Q & A Highlights

Q: Given the traction with retailers, who are the top-performing stores? A: Hamutal Yitzhak, CEO: We have not disclosed results on specific retail stores. However, revenue from US and Canadian retailers increased 88% and 111% sequentially. Significant customers include Walmart, KE, and Unify.